- Home
- HHH vs VKTX Comparison
HHH vs VKTX Comparison
Compare HHH & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHH | VKTX |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HHH | VKTX |
|---|---|---|
| Price | $67.48 | $35.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $90.00 | ★ $94.44 |
| AVG Volume (30 Days) | 357.6K | ★ 2.1M |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $1,474,892,000.00 | N/A |
| Revenue This Year | $14.04 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $61.01 | $22.96 |
| 52 Week High | $91.07 | $43.15 |
Technical Indicators
Market Signals| Indicator | HHH | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 57.20 |
| Support Level | $67.25 | $33.65 |
| Resistance Level | $71.20 | $35.66 |
| Average True Range (ATR) | 1.50 | 1.64 |
| MACD | 0.83 | 0.15 |
| Stochastic Oscillator | 99.00 | 81.73 |
Price Performance
Historical ComparisonAbout HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.